With the popularity of electronic products, there is a growing demand for digital systems to connect with the analog world to achieve changes, leading to an increasing need for Digital-to-Analog Converters (DACs). While designers are familiar with traditional voltage output DACs, many applications require current output DACs to provide precise, stable, high-resolution currents (tens or … Read more
Click below to follow and learn more about anti-cancer knowledge 👇 For patients with HER2 mutations in non-small cell lung cancer, past treatments have primarily involved chemotherapy, immunotherapy combined with chemotherapy, and anti-angiogenic therapy combined with chemotherapy. With the rise of antibody-drug conjugates (ADC), the treatment prospects for HER2 mutation patients are becoming increasingly clear. … Read more
After 2019, ADC drugs have been approved for marketing one after another, and the approval of Aidiqi in 2021 marked a milestone in the development of domestic ADC innovative drugs. The broad therapeutic prospects and huge market size have stimulated many pharmaceutical companies to ignite their enthusiasm for ADC drug research and development, leading the … Read more
Introduction Antibodies are one of the key components of ADC drugs, serving as precise guiding components with the functions of targeting and toxin delivery. They can specifically recognize the target antigens on the surface of tumor cells, delivering toxins to the tumor cells and mediating the localization and endocytosis of ADCs in tumor cells[1]. After … Read more
GUIDE Editor’s Recommendation Antibody-drug conjugates (ADC) remained popular in 2022. Enhertu redefined the treatment landscape for HER2 breast cancer, making headlines at major academic conferences like ASCO and ESMO; Kelun-Biotech approached a $10 billion license-out deal with multinational pharmaceutical company Merck, setting a new record for local pharmaceutical companies going abroad; the world’s first anti-CD79b … Read more
The Concept and Development History of ADC The treatment of tumors has always undergone a continuous transformation from theory to application, breaking and transforming again. As early as a century ago, scholars proposed the concept of antibody-drug conjugates (ADCs), vividly calling them “magic bullets,” aimed at targeting specific antigens that may exist on the surface … Read more
Please click the “Bio New Thinking” above to follow more exciting content! Written by / Jia Bei Pharmaceutical @ Bai Ao Yun Testing Reviewed by / Gu Du Pharmacist @ Bio New Thinking Antibody-drug conjugates (ADCs) are large molecule drugs formed by conjugating monoclonal antibodies with highly potent small molecule drugs via linkers, enabling targeted … Read more
Breast cancer, regarded as the “killer of beauty,” is a malignant tumor that severely threatens women’s health, with an increasing incidence year by year. Antibody-drug conjugates (ADC), as a new type of therapeutic drug, have become a hot research topic in the field of breast cancer due to their advantages of “high efficacy and low … Read more
Introduction Antibody-drug conjugates (ADCs) are “biological bullets” formed by conjugating cytotoxic drugs (payloads) to antibodies via a “linker.” They consist of five components: target, antibody, linker, payload, and conjugation method. Each part is crucial to the function of ADCs, but today we will focus on the linker that connects the antibody and payload, examining the … Read more
Since the first use of cytotoxic chemicals to treat cancer, oncologists have been searching for ways to enhance efficacy without significantly increasing overall toxicity to patients. One of the methods attempted to improve the killing effect on tumor cells is the use of cytotoxic agents with potency at picomolar or lower levels (such as microtubule … Read more